Partial SEC filing excerpts show no reported revenues for 2025 or 2024, total assets of $130,938,025 in 2025, and net losses of $39,740,269 (2025) and $39,425,839 (2024).

### Summary of what the company does

I cannot produce a substantive summary of what the company does because the text you provided is only a partial table of contents (Part I headings) from a filing. The excerpt lists section headings (Item 1: Business; Item 1A: Risk Factors; Item 1B: Unresolved Staff Comments; Item 1C: Cybersecurity; Item 2: Properties; Item 3: Legal Proceedings; Item 4: Mine Safety Disclosures) but contains no descriptive narrative or numeric data about the company’s operations.

What is present in the excerpt
- Table-of-contents entries for Items 1 through 4 of a Part I filing (Business, Risk Factors, Unresolved Staff Comments, Cybersecurity, Properties, Legal Proceedings, Mine Safety Disclosures).

What is missing (requested but not in the provided text)
- Company description of products/services and markets served
- Number of customers
- Number of employees
- Revenue
- Net income (or other income figures)
- Any other operational or financial details

If you paste the Item 1 (Business) section or the financial statements/Management’s Discussion & Analysis, I can produce a detailed, specific markdown summary including customers, employees, revenue, and income.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing first-in-class critical care products aimed at addressing unmet medical needs.

# Citius Pharmaceuticals, Inc.

## Overview
Citius Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cranford, New Jersey. The company focuses on the development and commercialization of first-in-class critical care products, particularly therapeutics that address unmet medical needs with lower development risks than new chemical entities.

### Product Focus
Citius Pharmaceuticals is developing three proprietary products:

1. **Mino-Lok**: An antibiotic lock solution designed to treat patients with catheter-related bloodstream infections (CRBSIs) by salvaging the infected central venous catheters (CVCs).
   
2. **Halo-Lido**: A corticosteroid-lidocaine topical formulation intended for the treatment of hemorrhoids. 

3. **NoveCite**: A mesenchymal stem cell therapy aimed at treating Acute Respiratory Distress Syndrome (ARDS).

Additionally, Citius Oncology, a majority-owned subsidiary, has gained approval from the FDA for **LYMPHIR**, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

### Business Model
Citius Pharmaceuticals' strategy is to provide therapeutic products with intellectual property and regulatory exclusivity while addressing significant market demands with a focus on reducing development and clinical risks. The company's core focuses include:
- Formulating new therapies based on existing drugs with established safety profiles.
- Expanding their portfolio through innovative applications and strategic partnerships.

### Market Size and Customers
Citius Pharmaceuticals targets a large and growing market:
- **Hemorrhoids**: Affect nearly 5% of the U.S. population, with approximately 10 million individuals annually experiencing symptoms.
- **CTCL**: The incidence rate for CTCL is estimated at about 0.5 per 100,000, translating to approximately 2,500 to 3,000 new cases in the U.S. yearly, which indicates a sizable addressable market.

### Financial Information
- **Employee Count**: The company employs a substantial number of professionals, although the specific number is not disclosed.
- **Revenue & Income**: Specific details regarding the company's total revenue and income are not given in the text provided. However, the addressable market for Mino-Lok is estimated to be approximately $500 million to $1 billion, indicating potential for significant revenue generation as the product advances in development.

### Growth and Development
Citius Pharmaceuticals has a history of market engagement and progressive steps in clinical trials. The company recently completed a pivotal study for Mino-Lok and has active development programs for its proprietary products. The FDA's approval of LYMPHIR indicates successful navigation through regulatory processes, and further approvals are anticipated as the company continues to develop its portfolio.

## Summary
Citius Pharmaceuticals, Inc. is positioned within critical care therapeutic segments, especially focusing on oncology and infection control. With its suite of innovative products, the company aims to capture market share in underserved medical areas. Its strategic navigation through clinical trials and regulatory frameworks reflects a robust approach to biopharmaceutical development and potential for significant future revenue.

Citius Pharmaceuticals, Inc.

10-K / December 23, 2025

10-K / December 27, 2024

10-K / December 23, 2025

Summary of what the company does